• Qlife Holding AB secured U.S. patent approval for core technology behind its Egoo decentralized biomarker-testing platform.
• Coverage targets the underlying platform architecture, including integrated sample mixing and optical measurement in a compact, automated system.
• Management framed the U.S. intellectual-property position as a strategic boost for partnering talks, alongside existing protection in Europe and China.
• Patent is expected to be formally issued once final USPTO administrative steps are completed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qlife Holding AB published the original content used to generate this news brief via Cision (Ref. ID: 20261013:BIT:3044:0) on October 14, 2026, and is solely responsible for the information contained therein.